StreetInsider.com News Articles

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

Mon, 24 Aug 2026 08:55:00 -0400

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions— Cleveland Clinic and Moffitt Cancer Center

SAN JOSE, Calif., Aug. 24, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

Mon, 24 Aug 2026 08:55:00 -0400

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions— Cleveland Clinic and Moffitt Cancer Center

SAN JOSE, Calif., Aug. 24, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

Mon, 24 Aug 2026 08:55:00 -0400

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions— Cleveland Clinic and Moffitt Cancer Center

SAN JOSE, Calif., Aug. 24, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

Mon, 24 Aug 2026 08:55:00 -0400

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions— Cleveland Clinic and Moffitt Cancer Center

SAN JOSE, Calif., Aug. 24, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

Mon, 24 Aug 2026 08:55:00 -0400

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions— Cleveland Clinic and Moffitt Cancer Center

SAN JOSE, Calif., Aug. 24, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

Mon, 24 Aug 2026 08:55:00 -0400

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions— Cleveland Clinic and Moffitt Cancer Center

SAN JOSE, Calif., Aug. 24, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

Mon, 24 Aug 2026 08:55:00 -0400

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions— Cleveland Clinic and Moffitt Cancer Center

SAN JOSE, Calif., Aug. 24, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

Mon, 24 Aug 2026 08:55:00 -0400

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions— Cleveland Clinic and Moffitt Cancer Center

SAN JOSE, Calif., Aug. 24, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 18 Aug 2026 08:45:00 -0400

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions—Moffitt Cancer Center and Cleveland Clinic

SAN JOSE, Calif., Aug. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 18 Aug 2026 08:45:00 -0400

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions—Moffitt Cancer Center and Cleveland Clinic

SAN JOSE, Calif., Aug. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 18 Aug 2026 08:45:00 -0400

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions—Moffitt Cancer Center and Cleveland Clinic

SAN JOSE, Calif., Aug. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 18 Aug 2026 08:45:00 -0400

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions—Moffitt Cancer Center and Cleveland Clinic

SAN JOSE, Calif., Aug. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 18 Aug 2026 08:45:00 -0400

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions—Moffitt Cancer Center and Cleveland Clinic

SAN JOSE, Calif., Aug. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 18 Aug 2026 08:45:00 -0400

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions—Moffitt Cancer Center and Cleveland Clinic

SAN JOSE, Calif., Aug. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 18 Aug 2026 08:45:00 -0400

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions—Moffitt Cancer Center and Cleveland Clinic

SAN JOSE, Calif., Aug. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 18 Aug 2026 08:45:00 -0400

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions—Moffitt Cancer Center and Cleveland Clinic

SAN JOSE, Calif., Aug. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a

Form 4 Anixa Biosciences Inc For: Jul 31 Filed by: KUMAR AMIT

Mon, 03 Aug 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260803/26854604.html

Form 4 Anixa Biosciences Inc For: Jul 31 Filed by: KUMAR AMIT

Mon, 03 Aug 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260803/26854604.html

Form 4 Anixa Biosciences Inc For: Jul 27 Filed by: Baskies Arnold M

Wed, 29 Jul 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260729/26831827.html

Form 4 Anixa Biosciences Inc For: Jul 27 Filed by: Baskies Arnold M

Wed, 29 Jul 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260729/26831827.html

Form 4 Anixa Biosciences Inc For: Jul 27 Filed by: KUMAR AMIT

Tue, 28 Jul 2026 10:20:00 -0400

si-local-file:///var/storage/secattach/20260728/26824227.html

Form 4 Anixa Biosciences Inc For: Jul 27 Filed by: KUMAR AMIT

Tue, 28 Jul 2026 10:20:00 -0400

si-local-file:///var/storage/secattach/20260728/26824227.html

Form 4 Anixa Biosciences Inc For: Jul 27 Filed by: KUMAR AMIT

Mon, 27 Jul 2026 15:25:00 -0400

si-local-file:///var/storage/secattach/20260727/26819240.html

Form 4 Anixa Biosciences Inc For: Jul 27 Filed by: KUMAR AMIT

Mon, 27 Jul 2026 15:25:00 -0400

si-local-file:///var/storage/secattach/20260727/26819240.html

Form 4 Anixa Biosciences Inc For: Jul 24 Filed by: KUMAR AMIT

Mon, 27 Jul 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260727/26816994.html